Scinovex
articleTop 1% cited

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

European Urology · 2019 · Vol. 75(5) · pp. 799–810
Börje LjungbergLaurence AlbigèsYasmin Abu‐GhanemKarim BensalahSaeed DabestaniSergio Fernandéz‐PelloRachel H. GilesFabian HofmannMilan HoraMarkus A. KuczykTeele KuuskThomas LamLorenzo MarconiAxel S. MerseburgerThomas PowlesMichael StaehlerRana TahbazAlessandro VolpeAxel Bex
Renal cell carcinoma treatmentRenal and related cancersEconomic and Financial Impacts of CancerMedicineSystematic reviewGuidelineMEDLINERenal cell carcinomaRandomized controlled trialEvidence-based medicineClinical trialMedical physicsFamily medicine

MeSH terms

Antineoplastic Agents, ImmunologicalCarcinoma, Renal CellHumansKidney NeoplasmsNephrectomyChemotherapy, AdjuvantWatchful WaitingMolecular Targeted Therapy

Funding

  • Amgen
  • Bristol-Myers Squibb
  • Pfizer
  • Bayer
  • GlaxoSmithKline
  • Novartis
  • Roche
  • Sanofi
  • Ipsen Biopharmaceuticals
  • Astellas Pharma
Citations
1,510
FWCI
175.25
field-weighted impact
References
74
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.